A randomized controlled pilot study of add-on therapy of CIM-MEG19 (standardized Andrographis paniculata formulation) in mild to moderate COVID-19
Karuna Shanker, Hrishikesh Rangnekar, Asmita Wele, Pravin Soni, Pranesh Gaikwad, Anirban Pal, Dnyaneshwar U Bawankule, Debabrata Chanda
Phytomedicine Plus, doi:10.1016/j.phyplu.2022.100398
Background: Traditional knowledge and scientific shreds of evidence strongly support the repurpose of Kalmegh (Andrographis paniculata, CIM-MEG19) as an alternate therapy for prophylactic management and treatment of severe acute respiratory syndrome coronavirus (SARS-CoV) and associated health disorders. Purpose: The study aimed to assess the efficacy and safety of the CIM-MEG19 (standardized A. paniculata extract formulation), a proprietary Ayurvedic medicine in the COVID-19 management, clinical recovery, and outcomes in terms of hospitalization days as well as any sign of severity due to drug-drug interaction between CIM-MEG19 TM and standard of care (SoC). Methods: A randomized, parallel-group, active-controlled interventional pilot clinical study was conducted. The Group-A subjects were assigned to CIM-MEG19 add-on to SoC treatment using modern medicine without antiviral drug whereas Group-B patients with SoC treatment using modern medicine and recommended antiviral drug for COVID-19 management. Eighty RTPCR (real-time polymerase chain reaction) positive and eligible COVID-19 patients of age >18 years, having mild or moderate severity, were enrolled. Results: Clinical improvement in reduction of symptoms showed significant (p<0.0001) results in the average days in subjects of group-A (Investigational intervention arm) compared to Group B (SoC). The RT-PCR investigation exhibited COVID negative for 50 % in CIM-MEG19 add-on and 47% in SoC treatment after 8-11 days. Similarly, biochemical investigations showed that CIM-MEG19 group-A had a significant (p ≤ 0.05) effect on C-Reactive Protein (CRP) and Interleukin-6 (IL-6) after 14 days of treatment. Additionally, improvement in D-Dimer, ESR, and LDH in CIM-MEG19 add-on therapy was also observed.
Conclusions: The study demonstrated an excellent safety profile, declining the severity of the infection and halting the disease advancement/progression. CIM-Meg19 might be used as a potential natural drug for treating COVID-19.
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
Supplementary materials Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.phyplu.2022.100398.
References
Aiims, Clinical guidance for sydromic management of suspected COVID-19 cases
Api, The Ayurvedic Pharmacopoeia of India, Part-I
Calabrese, Berman, Babish, Ma, Shinto et al., Synthesis, structure-activity relationships and biological evaluation of dehydroandrographolide and andrographolide derivatives as novel anti-Hepatitis B virus agents, Bioorg. Med. Chem. Lett,
doi:10.1016/j.bmcl.2014.03.060Coon, Ernst, Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy, Planta Med,
doi:10.1055/s-2004-818938Dean, Sullivan, Soe, OpenEpi: open source epidemiologic statistics for public health, version 3.01
Enmozhi, Raja, Sebastine, Joseph, Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in-silico approach, J. Biomol. Struct. Dyn,
doi:10.1080/07391102.2020.1760136Fleiss, Levin, Paik, Statistical Methods For Rates And Proportions, Formulas
Gupta, Khan, Singh, Constitutive inflammatory cytokine storm: a major threat to human health, J. Interferon Cytokine Res
Gupta, Vedula, Srivastava, Tamoli, Mundhe et al., Prospective, randomized, open-label, blinded end point, two-arm, comparative clinical study to evaluate the efficacy and safety of a fixed Ayurvedic regimen (FAR) as add-on to conventional treatment in the management of mild and moderate COVID-19 patients, J. Pharm. Bioallied Sci,
doi:10.4103/jpbs.jpbs_242_21Herold, Jurinovic, Arnreich, Lipworth, Hellmuth et al., Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19, J. Allergy Clin. Immunol,
doi:10.1016/j.jaci.2020.05.008Hu, Wu, Logue, Blondel, Lai et al., Andrographis paniculata (Chuān Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: A systematic review and meta-analysis, PloS One,
doi:10.1371/journal.pone.0181780Jain, Iyengar, Vaishya, Differences between first wave and second wave of COVID-19 in India, Diabetol. Metab. Syndr,
doi:10.1016/j.dsx.2021.05.009Kaushik, Dar, Kaushik, Yadav, Identification and characterization of new potent inhibitors of dengue virus NS5 proteinase from Andrographis paniculata supercritical extracts on in animal cell culture and in-silico approaches, J. Ethnopharmacol,
doi:10.1016/j.jep.2020.113541Liu, Zhang, Yang, Ma, Li et al., The role of interleukin-6 in monitoring severe case of coronavirus disease 2019, EMBO Mol. Med,
doi:10.1101/2020.03.01.20029769Premnath, Task force on repurposing of drugs for COVID-19: charting the path for India
Saxena, Singh, Kumar, Yadav, Negi et al., A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold™) in patients with uncomplicated upper respiratory tract infection, Phytomedicine,
doi:10.1016/j.phymed.2009.12.001Seifert, Jeitler, Stange, Michalsen, Cramer et al., The relevance of complementary and integrative medicine in the COVID-19 pandemic: a qualitative review of the literature, Front. Med,
doi:10.3389/fmed.2020.587749Sharifpour, Rangaraju, Liu, Alabyad, Nahab et al., C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19, PloS One,
doi:10.1371/journal.pone.0242400Srikanth, Sarma, Andrographolide binds to spike glycoprotein and RNA-dependent RNA polymerase (NSP12) of SARS-CoV-2 by in silico approach: a probable molecule in the development of anti-coronaviral drug, J. Genet. Eng. Biotechnol,
doi:10.1186/s43141-021-00201-7Valecha, Devi, Joshi, Shahi, Sharma et al., Comparative efficacy of AYUSH-64 vs chloroquine in vivax malaria, Curr. Sci
Wanjarkhedkar, Sarade, Purandare, Kelkar, A prospective clinical study of an Ayurveda regimen in COVID 19 patients, J. Ayurveda Integr. Med,
doi:10.1016/j.jaim.2020.10.008Who, R&D blueprint novel coronavirus COVID-19 therapeutic trial synopsis
Zhou, Fu, Zheng, Wang, Zhao et al., Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus, bioRxiv,
doi:10.1101/2020.02.12.945576
